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1. Introduction 
Allergy in general is a common problem in the community, when all aspects of allergy are 
considered, this condition may well represent the largest single medical problem seen in the 
United States today and probably in the world.(1) Allergic rhinitis is the commonest allergic 
disease. It alone is the sixth most prevalent chronic disease in the world, outranking heart 
disease. (2) There were six factors that stimulated us to choose this disease in our study: 
firstly, Allergic rhinitis is the commonest allergic disease in the world, affect 10-25% of 
population (3), secondly, Although it is not a life threatening but from an economic point of 
view, allergic rhinitis is not a minor problem based on figures reported elsewhere(4), thirdly, 
Till now, there is no curative treatment for allergic rhinitis except specific immunotherapy 
which have many side effects and not suitable for every patient especially when multiple 
allergens are implicated, which is commonest than single allergen.(5), fourthly, Serious side 
effects of pharmacotherapy used in treatment of allergic rhinitis especially steroids which 
reflected in recent years a trend of increasing use of alternative medicines(6-7),fifthly, Allergic 
rhinitis was frequently trivialized by patients and doctors (particularly non sufferers),this 
may be because it is not a fatal disease yet it remains a common cause of morbidity, social 
embarrassment and impaired performance either at school or in the work place, moreover , 
it may be complicated by a course of other diseases such as sinusitis, otitis media and 
asthma. (3-8) and lastly, in a previous studies, it has been proved that Nigella sativa is an 
effective treatment of asthma. It also showed an improvement in the associated nasal 
symptoms that accompanied asthma (9,10) Administration of black seed oil significantly 
reduced the level of allergen induced lung remodeling (11).  
Allergic rhinitis is a common disease, accounting for at least 2.5% of all physician visits, 2 
million lost school days per year, 6 million lost work days, and 28 million restricted work 
days per year. At least $ 5.3 billion is spent annually on prescription and over-the-counters 
medications for allergy(12) . Between 10 and 25% of the population is affected(3) and the 
prevalence in urban areas is increasing .The prevalence is lowest in children below age 5 , 
rises to a peak in early adulthood and declines thereafter. The 4 year remission rate reported 
to be 10% in males and 5% in females.(13)  
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N.S. is a an annual famous herb, the respect of which in the medical field is taken from a 
religious origin when the prophet Mohammed  advised people to use it in order to treat 
different diseases. The seeds of N.S are considered as carminative, stimulant, galactoguge, 
anti tussive, anti flu and anti flatulence e.t.c. (2). Anti allergic effects of N.S. was reported (2). 
The active ingredient is thymoquinone with its carbonyl polymer. (14) Recently reported 
study suggest the N. sativa could reduce the presence of the nasal mucosal congestion, nasal 
itching, runny nose, sneezing attacks, turbinate hypertrophy, and mucosal pallor during the 
first 2 weeks(15). Furthermore, N. sativa supplementation during specific immunotherapy of 
AR may be considered a potential adjuvant therapy (16) and it was equal therapeutic activity 
in relieving the symptoms of seasonal AR to cetirizine, without its side effects (17).  
1.1 AIm of the study 
To evaluate the therapeutic effect of systemic forms of black seed oil in allergic rhinitis  
2. Materials and methods 
2.1 Study population 
A total of 188 patients with allergic rhinitis symptoms of different severities (mild, moderate 
and severe) with age ranging from 6-45 years, were included in this study [Table 1]. This 
double blinded clinical trial was performed during the period between January 2009 to June 
2010 in the out- patient clinic of centre of allergy in Tikrit Teaching Hospital (TTH) in 
Salahuldean governorate, Iraq. The patients were either referred from medical or ENT 
departments, from the out patients in the same hospital and those who attended the allergy 
centre to have immunotherapy. 
2.2 Diagnosis of asthma and allergic rhinitis 
The diagnosis of asthma and classification was performed by specialist physicians based on 
the National Heart Blood and Lung Institute / World Health Organization (NHLBI/WHO) 
workshop on the Global Strategy for Asthma (18). Allergic rhinitis diagnosis was performed 
according to previously reported guidelines (19).  
2.3 Skin prick test 
The skin prick tests were performed for all patients and control and evaluated in accordance 
with European Academy of Allergy and Clinical Immunology subcommittee on allergy 
standardization and skin tests using standards allergen panel (Stallergen, France). The panel 
for skin test include: dust mite ( Dermatophagoides farina, Dermatophagoides 
peteronyssinus), Aleternaria, Cladosprium, Penicillum mixture, Aspergillus mixture, Grasses 
mixture, Feather mixture, Dog hair, Horse hair, Cat fur, Fagacae, Oleaceae, Betulaceae, 
Plantain, Bermuda grass, Chenopodium and Mugworth. All tests were performed in the 
outpatient Asthma and Allergy Centre, Mosul by a physician using a commercial allergen 
extracts (Stallergen, France) and a lancet skin prick test device. A wheal diameter of 3 mm or 
more in excess of the negative control was considered as positive test result.  
2.3.1 Allergen extracts for skin prick test 
Therapeutic vaccines containing allergen extracts were purchased from Stallergen, France. 
Both aqueous and glycenerated extracts were used to achieve a concentrate of 1:100 w/v of 
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the mixed extract. In standardized extracts the stock formulation was prepared by tenfold 
dilution. Separate vial was used for allergen extract to reduce proteolysis degradation. All 
extracts were stored at 8 0C . Therapeutic vaccine varied with each individual patient based 
on specific allergen identified during testing. Moist patients received a variety of 
aeroallergen combination.  
 
Variable  Active group Control group Total Number [%] 
Patients total number
Patients completed study 
Female/Male 
115
102 
58/44
95
86 
48/38
210
188 
106/82
Mild group 
 Total number 
 Patient completed study 
 Female/Male 
35 
31 
18/13
 
30 
27 
16/11
65 
58 
34/24
Moderate group 
 Total number 
 Patient completed study 
 Female/Male 
50 
44 
25/19
 
40 
37 
20/17
90 
81 
45/36
Severe group 
 Total number 
 Patient completed study 
 Female/Male 
30 
27 
15/12
 
25 
22 
12/10
55 
49 
27/22
Gender  
 Male  
 Female  
 
82 [43.6] 
106 [56.4] 
Age in year 
6 -15 
16-25 
26-35 
36-45 
 
60 [31.9] 
75 [39.8] 
36 [19.1] 
17 [9.0]
Duration in year  
Mild  
Moderate 
Severe  
 
1-4  
2-7 
2.5–11
Skin test 
Single  
Multiple  
 Two 
 Three  
 Four  
HDM 
Candida  
Molds  
Grass mixture 
Animal dander 
Other pollen 
 
63 [33.5] 
125 [66.5] 
76 [40.4] 
40 [21.3] 
9 [ 4.8] 
103 [54.7] 
70 [37.2] 
65 [34.5] 
58 [30.8] 
32 [17.0] 
43 [22.8]
Associated diseases
Conjunctivitis  
Asthma 
Sinusitis 
Urticaria 
Otitis media 
Polyps  
68 [66.6] 
33 [32.3] 
15 [14.7] 
12 [11.7] 
4 [3.9] 
4 [3.9]
 
43 [50] 
26 [30.2] 
17 [19.7] 
5 [5.8] 
3 [3.4] 
2 [2.3]
111 [59] 
59 [31.4] 
32 [17] 
17 [9] 
7 [3.7] 
6 [3.2]
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Variable  Active group Control group Total Number [%] 
Exacerbating factor
Allergen exposure 
URT infection 
Temperature change 
Smoke & irritants 
Hormonal  
89 [87.2] 
39 [38.2] 
26 [25.4] 
21 [20.5] 
4 [3.9]
 
64 [74.2] 
24 [27.9] 
22 [25.5] 
14 [16.2] 
2 [2.3] 
153 [81.4] 
63 [33.5] 
48 [25.5] 
35 [18.6] 
6 [3.2]
Severity  
Mild 
Moderate 
Severe  
31 [30.4] 
44 [43.1] 
27 [26.5]
 
27 [31.4] 
37 [43.0] 
22 [25.6] 
58 [30.8] 
81 [43.1] 
49 [26.1]
Pattern  
Seasonal 
 Mild 
 Moderate  
 Severe  
Pereniall  
 Mild  
 Moderate 
 Severe  
41 [40.2] 
11 [26.8] 
20 [48.8] 
10 [24.4] 
61 [59.8] 
20 [32.8] 
24 [34.3] 
17 [27.9]
 
37 [43.0] 
9 [24.3] 
20 [ 54.1] 
8 [21.6] 
49 [57.0] 
18 [36.7] 
17 [34.7] 
14 [28.6]
78 [41.5] 
20 [25.6] 
40 [51.3] 
18 [23.1] 
110 [58.5] 
38 [34.5] 
41 [37.3] 
31 [28.2]
Family atopy  
Mild  
 Atopic  
 Non-atopic  
Moderate  
 Atopic  
 Non-atopic 
Severe  
 Atopic  
 Non-atopic 
 
11 [35.5] 
20 [64.5] 
 
21 [47.7] 
23 [52.3] 
 
17 [63] 
10 [37]
 
 
13 [48.1] 
14 [51.9] 
 
19 [51.4] 
18 [48.6] 
 
14 [63.6] 
8 [36.4]
 
24 [41.3] 
34 [58.7] 
 
40 [49.3] 
41 [50.7] 
 
31 [63.2] 
18 [36.8]
IgE IU/ml 
 Mild  
 Moderate  
 Severe  
143 
176 
393
 
168 
188 
361
Table 1. Patients characteristics at time of enrolled in the trial. 
2.4 Determination of total serum IgE 
ELISA was performed to estimate the total serum IgE level as a serological marker for 
treatment response monitoring.(20) Total serum IgE was determined by enzyme linked 
immunosorbant assay kit (Biomaghreb). Results were interpreted as allergy not probable if 
serum IgE was lower than 20 IU/ml, allergy is possible if IgE value is between 20 and 120 
IU/ml and allergy is very probable if IgE is more than 120 IU/ml. 
2.5 Classification of patients 
In classifying the patients, two types of classification were adopted(3,5)  
According to severity of symptoms. They were also sub classified into the following: mild 
group :A total 58 patients (31 active and 27 control); Moderate group: A total 81 patients (44 
active and 37 control); and Severe group: A total 49 patients (27 active and 22 control) 
According to allergens. The patients were sub classified into the following :  
- Seasonal class: A total 78 patients (41 active and 37 control). 
- Perennial class: A total 110 patients (61 active and 49 control).  
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2.6 Family history of allergy 
Because allergic diseases are familial diseases, some emphasis was laid on the families of 
patients to know the percentage of them that had allergic diathesis.  
3. Systemic use of the black seed oil 
The herb was given in the form of capsules, one capsule three times a day .Each capsule was 
about 0.6-0.8 gm of oil (which is about half of the dose that used in asthma in a previous 
study)(9) The control group received same shaped capsules but they contained ordinary food 
oil. The treatment was given for 6 weeks for both groups . The results were recorded on the 
patient’s questionnaire each visit .The same routine physical examination and laboratory 
investigations as mentioned earlier were done and recorded in addition to the clinical 
evaluation which was done according to the following criteria:  
3.1 Clinical assessment (symptom score) 
During each visit, the patient was examined clinically for vital signs and questioned about 
the improvement in his day and night symptoms (Rhinorrhoea, nasal obstruction, paroxysm 
of sneezing, night snoring, daily physical activities, school attendance and affection of life 
quality). Symptom score was of 4 points scale (0-3) according to the classification of rhinitis 
symptoms as specified by:  
0. No symptoms. 
1. Mild symptoms: Symptoms not interfere with sleep, normal daily activities, (sports, 
leisure), no trouble of some symptoms, sneezing (not more than 3 in each attack or 
paroxysm), with mild runny nose (of no more than 1hour).(3,5)  
2. Moderate symptoms: Are of one or more items of the following: abnormal sleep, 
impairment of daily activities, (sports, and leisure), problems caused at work, at school 
with troublesome symptoms: longer attack > 1h. -<8 with uncomfortable stuffy, runny 
nose, sneering 4-10 sneeze each attack. (3,5)  
3. Severe symptoms: The same as moderate but more severe, more nasal blockage and 
sleep interference with severe distressing stuffy, runny nose for more than 8h. attack 
with sneeze more than 10 times each paroxysm. (3,5)  
3.2 Tolerability to the exacerbating factors 
Many precipitating factors such as aeroallergen exposure, cold exposure, infection 
(sinusitis), drugs ...etc. may precipitate the condition, so the response to the exacerbating 
factors were assessed in each visit by skin test.  
3.3 Other associated allergic diseases 
Other allergic diseases such as asthma, conjunctivitis and urticaria were also recorded in 
each visits. 
3.4 Side effects 
Side effects that were shown by the patients were recorded for both systemic and nasal uses.  
3.5 Statistical analysis 
CHI square analytic system (X2) with Yates correction was used to compare between active 
and placebo groups. However, Chi Square is calculated only if the expected cell frequencies 
www.intechopen.com
 
Allergic Rhinitis 
 
202 
are equal to or greater than 5. While Fisher Exact Probability Test is used if some cells are 
less than five. Student t test is used to determine the significance of IgE differences between 
the groups.  
4. Results 
For systemic trial, a total of 210 patients were included in the study. Of them 115 patients 
received the treatment [active group] and 95 patients were the controls. The patients were 
divided according to their disease severity, and each of the above groups was subdivided 
into active and control groups. As mentioned earlier, 188 patients completed the course of 
treatment in this study while 22 patients withdrawn from the study [ Table 1]. 
4.1 Age and sex frequency distribution 
The eligible patients for analysis were subdivided into 3 groups as follow:  
Mild group: A total of 58 patients were included, of them: 31 patients (18 female and 13 
male) were mild active group and 27 patients (16 female and 11 male) were mild control 
group. Mild group patients accounts for 30.8% of the total . 
Moderate group: A total of 81 patients were included , of them : 44 patients (25 female and 
19 male) were moderate active group and 37 patients (20 female and 17 male) were 
moderate control group. Moderate group patients accounts for 43. 1% of the total.  
Severe group: A total of 49 patients were included, of them: 27 patients (15 female and 12 
male) constitute the severe active group while 22 patients (12 female, and 10 male) constitute 
the severe control group. Severe group patients accounts for 26.1% of the total. Male patients 
account for 43.6% and female ones account for 56.4% of total patients. The highest frequency 
of AR is in the age group of 16 -25 years and then the declines with age.  
Frequency distribution of the patients according to the duration of AR : Severe group had 
the longest duration of the diseases which was from 2.5 years-11 years, while mild group 
had the shortest duration range which was from 1 years- 4 years. 
Classification of the patients according to allergen's type:  
One of the important classification of the allergic rhinitis depending on the type of 
exacerbating allergen into the seasonal and perennial type. Perennial type ( 110 patient, 
58.5%) was more common than seasonal type (78 patient, 41.5%).  
4.2 Monthly distribution of the patients 
The monthly distribution of the patients indicated that 63.2% of cases were reported in 
March, April and May.  
4.3 Exacerbating factors 
The potent exacerbating factor in both groups was allergen exposure which account for 
87.2% ,(89 patients) in active group and 74.2% (64 patients) in control group. The upper 
respiratory tract infection forms 38.2% ,(39 patients) in active group and 27.9% ,(24 patients) 
in control group. This is followed by temperature and humidity changes with cold exposure 
which was 25.4%,(26 patients) in active group and 25.5% ,(22 patients) in control group. 
Then smoke and irritants factor which was about 20.5% ,(21 patients) in active group and 
16.2%,(14 patients) in control group .The last exacerbating factor that affect the disease in the 
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studied patients was hormonal factor (i.e. pregnancy) which was 3.9% ,(4 patients) in active 
group and 2.3% ,(2 patients) in control group.  
4.4 Family atopic diathesis 
As it is clear from the history of patients as shown in Table 3: atopic family diathesis with 
positive family history of allergy (in any form of allergy as asthma, eczema, and allergic 
rhinitis) was found in 41.3% (24 patients) of total mild group (13 control and 11 active) .This 
increased to 49.3% (40 patients) of total moderate group (19 control and 21active) .While the 
highest incidence was in severe allergic rhinitis group which was 63.2% (31 patients) (14 
control and 17 active) .This means that the disease is generally more severe in patients of 
atopic diathesis or tendency. 
4.5 Associated diseases 
Conjunctivitis was the most common associated disease which accounted for 66.6% (68 
patients) of total active group and 50% (43 patients) of total control group. Asthma was the 
second common associated disease. In active group it is accounted for 32.3% (33 patients) 
and in control group it is 30.2 (26 patients) while sinusitis which comes thirdly, accounted 
for 14.7% (15 patients) of active group and 19.7% (17 patients) of control group. The lowest 
associated disease was nasal polyposis which account for 3.9% (4 patients) of total active 
group and 2.3% (2 patients) of total control group.  
4.6 Skin test results 
In 33.5% of patients (63 patients) the test was positive to only one allergen and in 66.5% (125 
patients) was positive to multiple allergen. Double allergen positive skin test results form 
40.4% (76 patients), while triple allergen positive skin test results form 21.3% (40 patients) and 
lastly quadrant allergen positive skin test results form 4.8% (9 patients) of total 188 patients. 
For frequency distribution of the skin tests result according to allergens type, the highest 
incidence was HDM which accounted for 54.7% (103 patients), then Candida albicans 37.2% 
(70 patients). Animal dander account for 17% (32 patients), forms the lowest frequency.  
4.7 IgE serum level 
Serum IgE mean was 143 IU/ml in mild active and 168 IU/ml in mild control groups and 
were lower than those of the moderate groups (active,176 IU/ml; control, 188 IU/ml). This 
in turn was less than that of severe allergic rhinitis of both active (393 IU/ml) and control 
(361 IU/ml) groups.  
4.8 Effects after 6 weeks systemic treatment 
4.8.1 Symptomatic response: [Table 2] 
Mild group response: In mild active group,19 patients out of 31,(61.3%), became free from 
symptoms after a three week of treatment with black seed oil .This percentage is considered 
highly significant (P=0.000) when it is compared with mild control group of which only 4 
patients out of 27 (14.8%) , became free from symptoms. After six weeks of treatment, the 
results of mild group are as following : 30 patients (96.7%) did not show symptoms .This 
results is highly significant (P=0.000) when it is compared with mild control group of which 
only 7 patients (25. 9%) did not show symptoms. 
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Group Active group Control group 
0W 3W 6W P value 0W 3W 6W P value 
 Mild  Symptomatic 31 12 1  27 23 20  
(100%) (38.7%) (3.2%)  (100%) (85.1%) (74.5)  
Symptom free 0 19 30 0.000 0 4 7 NS 
(0%) (61.3%) (96.7%)  (0%) (14.8%) (25.9%)  
Moderate  Symptomatic 44 21 9  37 32 29  
(100%) (47.7%) (20.4%)  (100%) (86.4%) (78.3%)  
Improved 0 17 21  0 5 6  
(0%) (38.6%) (47.7%)  (0%) (13.5%) (16.20%)  
Symptom free 0 6 14 0.000 0 0 2 NS 
(0%) (13.6%) (31.8%)  (0%) (0%) (5.4%)  
Severe  Symptomatic 27 17 11  22 19 17  
(100%) (62.9%) (40.7%)  (100%) (86.3%) (77.2%)  
Improved 0 8 10  0 3 5  
(0%) (29.9%) (37%)  (0%) (13.6%) (22.7%)  
Symptom free 0 2 6 NS 0 0 0 NS 
(0%) (7.4%) (22.2%)  (0%) (0%) (0%)  
Table 2. Symptomatic response at 6 weeks systemic use  
Moderate group response: In moderate group, after 3 weeks of treatment, 17 patients out of 
44 (38.6%) demonstrate partial improvement while 6 patients (13.6%) became symptoms free 
patients. So 23 patients out of 44 (52.2%) demonstrated either partial or total improvement of 
their signs and symptoms. These results are highly significant (P=0.004) as compared with 
moderate control group from whom only 5 patients out of 37 (13.5%) got partial 
improvement at the end of 3 weeks . At the end of 6 weeks treatment in moderate active 
group; 21 patients (47.7%) show partial improvement and 14 patients (31.8%) were 
symptoms free. Thus, the total improved patients of moderate active group at the end of 6 
weeks (partially and a totally improved) were 35 patients out of 44 , nearly about 79.5% . 
This is significant with (P=0.02) as compared with moderate control group at 6 weeks 
treatment of which 6 patients (16.2%) got partial improvement while only 2 patients (5.4%) 
got no symptoms. Therefore in moderate control group 8 patients (12.5%) improved 
(partially ,and totally) at the end of the 6 weeks. 
Severe group responses: For severe active group, 8 patient out of 27 (29.9%) show partial 
improvement while 2 patients(7.4%) became free from symptoms after 3 weeks treatment with 
black seed capsules .This indicate that 10 patients (36.3%) demonstrate treatment benefit 
(partially or totally). While in severe control group, 3 patients out of 22 (13.6%) got partial 
improvement after 3 weeks of treatment with ordinary food oil capsules and none became non 
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symptomatic. At the end of 6 weeks of treatment for severe active group: 10 patients (37%) 
were got partial improvement while 6 (22.2%) got symptoms free. Thus collectively improved 
patients were 16 patients (59.2%). Clinically, this is considered a good result and is statistically 
significant (P=0.026) as compared with the results of severe control group were only 5 patients 
(22.7%) got partial improvement. The differences in clinical improvement between 3 and 6 
weeks treatment duration was highly significant (P=0.000) as compared to baseline for both 
mild and moderate active group. However, it was not significant in case of severe group.  
4.9 Serum IgE 
The mean serum IgE level in mild active group decreased from 143 IU/ml at the baseline 
estimation to 91 after a 6 week treatment with N. sativa oil, while in mild control group, it 
decreased from 168 IU/ml to 131 IU/ml after a 6 week treatment with ordinary food oil. In 
moderate active group, it decreased from 176 IU/ml at the baseline estimation to 127 IU/ml 
after 6 weeks of treatment while for moderate control group also there was reduction in the 
IgE average level from 188 IU/ml to 152 IU/ml. In severe group, the IgE average level of 
severe active group decreased from 393 IU/ml to 354 IU/ml and the same thing occurred in 
control group which decreased from 361 IU/ml at the baseline estimation to 335 IU/ml at 
the end of the 6 week treatment. The reduction in serum IgE means level pre- and post- 
treatment was significant for both active and control groups, however, there was a 
significant differences between active and control groups [Table 3]. 
 
  Mean IgE IU/ml [SD]
Mild Moderate Severe 
Active  Pretreatment 143 [8.9] 176 [11.3] 393 [18.7] 
Post treatment 91 [7.1] 127 [7.7] 354 [12.3] 
Difference 52 49 39
P value 0.000 0.000 0.000 
Control Pretreatment 168 [9.6] 188 [10.1] 361 [16.4] 
Post treatment 131 [10.4 ] 152 [12.5] 335 [17.5] 
Difference 37 36 26
P value 0.000 0.000 0.000 
P value for difference between 
active & control 
0.000 0.000 0.007 
Table 3. Effect of systemic treatment with N. sativa on IgE [IU/ ml] serum level.  
4.10 Tolerability to the exacerbating factors 
Improvement in tolerability of the exacerbating factors in total active group and total control 
group are shown in Table 6. The response to allergen exposure has improved from 24.5% 
after 3 weeks (P=0.001) treatment to 37.5% at 6 weeks (P=0.000) treatment in the active 
group while in control group, the improvement was much less. The allergen exposure 
tolerability was significant during the treatment course (P=0.000), however, there was no 
significant difference between 3 and 6 weeks of treatment period. The response to 
temperature variation has also improved to about 7.8% at the end of 3 weeks (P=0.01) and to 
about 11.7% at the end of 6 weeks treatment in active group (P=0.001) .This is better than 
that of control group which was about 2.3 at the end of 3 weeks and increased to 4.6 (4 
patients) at the end of 6 weeks . Another environmental factor that showed improvement 
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was exposure to irritant gases which increased from 5.8% at the 3 week (P=0.03) treatment 
in active group to 9.8% at the end of 6 weeks (P=0.00 3) while in control group, a minor 
improvement occurred, which was from 2.31 after 3 weeks of treatment to 3.4% after 6 
weeks of treatment. [Table 4].  
 
Variable Active groupNumber [%] Control groupNumber [%] P value  
Allergen exposure 
3 week 
6 week 
P value 0,3 & 6 weeks 
 0 & 3 weeks 
 0 & 6 weeks 
 3 & 6 weeks 
 
25 [24.5] 
38 [37.2] 
0.000 
0.001 
0.000 
NS 
 
3 [3.4] 
5 [5.8] 
NS 
NS 
NS 
NS 
 
0.000 
0.000 
Temperature change 
3 week 
6 week 
P value 0,3 & 6 weeks 
 0 & 3 weeks 
 0 & 6 weeks 
 3 & 6 weeks 
 
8 [7.8] 
[11.7] 
NS 
0.01 
0.001 
NS 
 
2 [2.3] 
2 [2.3] 
NS 
NS 
NS 
NS 
 
NS 
0.02 
Irritant exposure  
3 week 
6 week 
P value 0,3 & 6 weeks 
 0 & 3 weeks 
 0 & 6 weeks 
 3 & 6 weeks 
 
6 [5.8] 
10 [9.8] 
NS 
0.03 
0.003 
NS 
 
4 [4.6] 
3 [3.4] 
NS 
NS 
NS 
NS 
 
NS 
NS 
Table 4. Tolerability to the exacerbating factors 
4.11 Symptomatic response in associated allergic illnesses 
The common associated allergic disease allergic rhinitis was allergic conjunctivitis which 
accounts for 66.6% (68 patients) and this was decreased to 21.5% (22 patients) at the 3 weeks 
(P=0.000) treatment then became 17.6% (18 patients) at the end of 6 weeks (P=0.000) 
treatment. While in control group, conjunctivitis affect 50% (43 patients) which showed 
some improvement after 3 weeks to 44.1% (38 patients) and decreased lastly to 39.5% (34 
patients) at the end of 6 weeks treatment . The differences between active and control 
groups was significant for both 3 and 6 weeks course treatment (P=0.001). Table 5. 
Asthma which was presented in 32.3%( 33 patients) of active group decreased to 21.5% (22 
patients) after 3 weeks and then decreased to 18.6% (19 patients) at end of 6 weeks while in 
control group, 30.2% (26 patients) have asthma which showed improvement by decreasing 
in symptomatic patients to 26.7% (23 patients) at 3 weeks treatment, then decreasing to 
24.4% (21 patients) at the end of 6 weeks treatment .however, the differences between active 
and control groups was not significant. Table 5.  
The last associated disease was urticaria which showed some improvement : 9.8% (10 
patients) were had symptoms at the beginning of the study and decreased to 6.8% (7 
patients) at 3 weeks treatment which then decreased to 4.9% (5 patients) at the end of 6 
weeks. While in control group, 8.1% (7 patients) have symptomatic urticaria decreased to 
6.9% (6 patients) by 3 weeks and remained the same at the end of 6 weeks treatment. The 
demonstrated differences between active and control groups was not significant. Table 5.  
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Variable Active group Number [%] Control group Number [%] P value  
Conjunctivitis  
0 week 
3 week 
6 week 
P value 0,3 & 6 weeks 
 0 & 3 weeks 
 0 & 6 weeks 
 3 & 6 weeks 
 
68 [66.6] 
22 [21.5] 
18 [17.6] 
0.000 
0.000 
0.000 
NS 
 
43 [50] 
38 [44.1] 
34 [39.5] 
NS 
NS 
NS 
NS 
 
0.03 
0.001 
0.001 
Asthma 
0 week  
3 week 
6 week 
P value 0,3 & 6 weeks 
 0 & 3 weeks 
 0 & 6 weeks 
 3 & 6 weeks 
 
33 [32.3] 
22 [21.5] 
19 [18.6] 
NS 
NS 
0.03 
NS 
 
26 [30.2] 
23 [26.7] 
21 [24.4] 
NS 
NS 
NS 
NS 
 
NS 
NS 
NS 
Urticaria 
0 week  
3 week 
6 week 
P value 0,3 & 6 weeks 
 0 & 3 weeks 
 0 & 6 weeks 
 3 & 6 weeks 
 
10 [9.8] 
7 [6.8] 
5 [4.9] 
NS 
NS 
NS 
NS 
 
7 [8.1] 
6 [6.9] 
6 [6.9] 
NS 
NS 
NS 
NS 
 
NS 
NS 
NS 
Table 5. Symptomatic response in associated allergic illness. 
 
Group Sub group Improved patients on 3 
and 6 weeks 
Withdrawal effect on improved 
patients 
3 weeks 6 week Patients with 
recurrence of 
symptoms 
Not symptomatic 
Patients 
Mild 
AR group (58) 
Active group 
31 
19 
61.3% 
30 
96.7% 
25 
80.6% 
5 
16.1% 
Control group 
27 
4 
14.8% 
7 
25.9% 
2 
7.4% 
5 
18.5% 
P value   0.000  
Moderate 
AR group(81) 
Active group 
44 
23 
52.2% 
35 
79.5% 
32 
72.7% 
3 
6.8% 
Control group 
37 
5 
13.5% 
8 
21.6% 
3 
8.1% 
5 
13.5% 
P value   0.009  
Severe 
AR group (49) 
Active group 
27 
10 
37.3% 
16 
59.2% 
14 
55.5% 
2 
7.4 
Control group 
22 
3 
13.6% 
5 
22.7% 
2 
9% 
3 
13.6% 
P value   NS  
Table 6. Two weeks systemic oil treatment with drawl effect 
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4.12 Factors associated with poor response to systemic NS treatment in AR 
The following factors seem to be associated with poor response to the systemic herb treatment 
[ Table. 6]: Multiple allergic diseases in the same patients, High IgE serum level, Gender 
(female), Perennial type more than seasonal one, Atopic diathesis, and Older age group.  
4.13 Two weeks systemic oil treatment withdrawal effect 
Two weeks systemic oil treatment with drawl effect is shown in Table 9. In mild active 
group, from 96.7% that improved at 6 weeks treatment with black seed oil, 80.6% had 
recurrence of their symptoms which was significant (P=0.000) when compared with mild 
control group. The same pattern reported for moderate group in which, from 79.5% 
improved at the end of 6 weeks NS oil treatment, 72.7% had recurrence of their symptoms 
which was significant (P=0.009) as compared to control group. Severe group also showed no 
significant difference in recurrence rate. 
4.14 Side effects 
The side effect of systemic NS treatment was diarrhea (10.7%) and nasal dryness (0.9%). 
5. Discussion 
Allergic rhinitis represents a global health problem. It is a common disease worldwide by 
which at least 10-25% of the population is affected and its prevalence is increasing. Although 
allergic rhinitis is not usually a severe disease but it alters the social life of patients and 
affect school performance and work productivity, and so, the costs incurred by rhinitis are 
substantial. (2) New knowledge about the mechanisms underlying allergic inflammation of 
the air ways has resulted to better therapeutic strategies, like immunotherapy with 
engineered allergen. Even trails of laser surgery for treatment of AR by laser turbinectomy 
(Tiny biopsy specimens) with local destructive effect of laser energy on the glandular acini 
and on the surrounding cholinergic nerve fibers which leads to decrease nasal secretions.(21). 
But still pharmacotherapy is the corner stone in the management of this illness, followed by 
immunotherapy(22). All these therapeutic strategies have many side effects, some of them 
may prove dangerous or even lethal, and in addition, there is no curative therapy.  
One of the good substitutions is the use of herbal medicine and one of the ancient herbs that 
was used medically for many diseases was black seed extract(23). This herb has been used for 
many diseases since no signs of toxicity or serious side effects were known in antiquity (24). 
The role of herbal medicine in allergic rhinitis as an effective therapy has not been studied 
extensively (15,16,17,25) and up to our knowledge, the use of topical N.S extract in treating A.R 
has not been studied yet. Although few studies have been conducted to illustrate the 
possibility of therapeutic effect of this herb on other allergic diseases like asthma(9,2,10,11,26) 
and allergic disease of the skin like urticaria(27).  
Females were affected more than males. This may be due to the fact that most of our 
patients came from rural areas where females used to work long hours in the fields. Other 
studies showed no sex difference or slight male predominance (8) . About 71.7% of the 
patients were less than 25 years old which means that the onset mainly started during the 
childhood and adolescence. This goes in line with other studies (28) because allergy is a less 
common cause of rhinitis in elderly as compared with other forms of rhinitis like atrophic 
rhinitis (3) . The disease duration has a big correlation with the severity of the disease since 
www.intechopen.com
Evaluation of Therapeutic Efficacy of  
Nigella sativa (Black Seed) for Treatment of Allergic Rhinitis 
 
209 
the shortest duration was of mild type and the longest duration was of the severe allergic 
rhinitis group. This may be due to the fact that chronicity of the disease leads to more 
allergen exposure which, in turn, leads to more non specific hyper reactivity. Non specific 
nasal hyper reactivity is an important feature of chronic allergic rhinitis and it is defined as: 
increase nasal response to a normal stimuli resulting in sneezing, nasal congestion and/or 
secretion(3,8) which lastly leads to more severe and chronic disease.  
Perennial type rhinitis were more than seasonal type. This may be due to more exposure 
since perennial allergens are present every were and at any time. The peak incidence 
occurred in spring season (from March to May with highest level in the April).This is due to 
the peak time for tree pollinosis in this area happens during these months which include 
exacerbation of seasonal type AR as well as perennial type . These results contradicts with 
the results of some other studies which were done in different geographical areas with 
different ecological environments (29) .  
The highest aggravating factor was allergen exposure simply because of the agricultural 
nature of the areas with more pollinosis and dampness, then upper respiratory tract 
infection followed by temperature changes then irritants and lastly hormonal factor. AR has 
mainly a bad course in the pregnant women since nasal obstruction may be aggravated by 
the pregnancy itself. (3,5) Allergic disease mainly worsened during pregnancy. This is proved 
by the following physiological and epidemiological observations(5) :  
The major physiologic factors are the direct and indirect effects of pregnancy associated 
hormones on nasal mucosa, that is estrogen cause nasal mucosal swelling, possibly through 
stimulation of local Ach production(5).  
 Cyclic changes in human female nasal mucus are characterized by the formation of 
large ferns during ovulation followed by their disappearance premenstrual. (5)  
 Recent ultrastructrual and histochemical studies have revealed the increased activity of 
nasal mucous glands during pregnancy. A change similar to that is found in estrogens 
and progesterone contraceptive users. (5)  
 Pregnancy associated hormones may indirectly affect the nose through their circulatory 
effect. The increased circulating blood volume during pregnancy combined with nasal 
vascular smooth muscle relaxation for progesterone may contribute to the nasal 
mucosal congestion that occurs frequently during pregnancy. Epidemiologic 
observations showed that allergic rhinitis may occur in up to 20% of the population of 
women of child bearing age. (5)  
It has been noticed that patients with AR have a strong family history of allergic disease. 
This finding is in accordance with well documented fact in allergic disease. (30-32)the 
commonest associated illnesses was allergic conjunctivitis which may be as an entity 
associated with allergic rhinitis due to the same mechanism with the same allergen. Yet, it 
may be a reflex of histamine granules degranulation and it is considered one of allergic 
rhinitis co-morbidities.(3) Allergic asthma comes secondly in associated disease’s frequency 
suggesting the concept that say "one air way, one disease". (33) Sinusitis is also one of the 
associated diseases and contributors to allergic rhinitis.(8,34)  
The commonest allergen implicated is house dust mite (HDM) which may be the worldwide 
commonest cause of allergic rhinitis.(35) One example to the importance of (HDM) in 
respiratory allergens is that the incidence of the atopy in southern France is 30% but the 
prevalence of allergic asthma and rhinitis is greater in the low land compared to the ALPS. 
The reason for this difference in the prevalence of allergies (in the same population type and 
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country) is considered to be the lower HDM population found above 1500 meters, and 
inhalant allergic patients are cleared an Alpine holiday despite the cold weather and 
exercise.(36) The severe symptoms patients had higher total serum IgE level then moderate 
symptomatic patient which in turn had higher level then mild symptomatic one .From this 
we can conclude that then increased in total serum IgE level correlates with the severity of 
the diseases.  
The mild and moderate active groups patients showed excellent improvement in clinical 
symptoms at the 3 and 6 week extract treatment which is statistically a highly significant as 
compared with control groups. The severe group also showed a good improvement in 
clinical symptoms for active group but was not statistically significant for 3 weeks treatment 
course. However, the treatment effect was statistically significant after 6 weeks course of 
therapy with black seed oil. The response to treatment in the severe group was lower than 
that in mild and moderate groups and this may be due to more associated co-morbidities 
especially asthma which may need higher doses of N.S. The improvement effect that is seen 
in different groups may be related to the antihistaminic activity of nigellon through 
membrane stabilizing action(37) , Anticholinergic activity by competitive property of the 
pinene(27), Anti inflammatory effect of thymoqunone by effect on cyclo oxyginase & lipo 
oxyginase pathways) (29,38) , immunomodulatory activity, and antioxidant activity.(23) 
The results also showed that the seasonal type has better responses than the perennial type 
which may be due to less nasal hyper reactivity appears because of less exposure to 
allergens (seasonal exposure only which don’t continue very long ) and decrease in the level 
of pollination may occur through this 6 weeks treatment leads to decrease the triggering 
factor which result in the decrease of allergic reaction associated with the stabilizing action 
of N. sativa extract which leads to better response and an improved clinical state.  
Males patients show better treatment responses .This may be due to that males had less 
allergen exposure because of agricultural nature of this area which depends on females and 
hormonal changes in female through menstrual cycle changes affect the nasal mucosa and 
enhance disease exacerbations .  
IgE level estimation by ELISA showed no switching of any patients from probable allergic 
group to non allergic group with increased level in some patients even after taking N. sativa 
extract for 6 weeks. The average of each group patients showed some decline in their level 
than that of the baseline estimation but this reduction was significant for active and control 
groups. However, the reduction in serum IgE following 6 weeks of black seed treatment was 
higher as compared to control group. 
Salem (39), reported that administration of nigellone to children and adults during the 
treatment of asthma, decreased the IgE level and eosinophil count. The reduction in total 
serum IgE level in control group may be a reflection of reduction in allergen exposure. The 
patients improved clinically without reduction in total serum IgE level to the level of non 
allergic individuals was due; firstly, measurement of total serum IgE level is not a measure 
of a specific IgE Ab which more specific predictor of atopy (28) . Secondly, since mast cell-
bound and non circulating IgE Ab are functionally important in initiating atopic reaction 
upon exposure to allergen. Measurement of the total quantity of IgE fixed to high affinity 
mast cell and basophile receptors (FCER1) might be more relevant to atopy than serum 
circulating IgE Ab but since there is no technique for making such measurement currently, 
there is only an estimation of skin mast cell-bound IgE by thresholds dilution skin testing 
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with heterologous anti-IgE that show the tissue IgE level is much higher in atopic 
individuals than the normal population. (28)  
Improvement in tolerability to the exacerbating factors in active group, as it is compared 
with the control group after systemic treatment, may be due to the stabilizing effect of N.S 
on mast cell granules and antihistaminic properties of nigellone thymoquinone and 
subsequently prevent histamine release from macrophages, intracellular calcium release, 
protein kinase C activation and oxidative energy metabolism (40). In a recent study, addition 
of NS seed to immunotherapy significantly increase the phagocytic and intracellular killing 
activities of PMNs in patients with AR (16). Furthermore, NS inhibits the COX and 5-
lipoxygenase pathways of arachidonic acid metabolism and decrease the synthesis of 
thromboxane and leukotrines (23, 41, 42). Since leukotrines are a potent mediators that play a 
major role in allergic diseases including allergic rhinitis and histamine plays an important 
role in immediate hypersensitivity reactions, thus the above findings may explain the 
mechanism mediating the efficacy of NS in allergic diseases (2,16).  
Improvement in associated allergic symptoms of conjunctivitis, asthma, and urticaria in 
active groups was more than that of control groups revealed clearly the multiple anti 
allergic actions of N. sativa extract. This may be due to augmentation of PMN function 
induced by N. sativa seed oil (16, 39), antihistaminic activity (40), antioxidant activity (43), 
inhibition of prostaglandin production (44) and antiiflamatory activity (45). 
Factors associated with poor response to systemic NS treatment include: a) Multiple allergic 
disorders which may need more dose because the multiple allergic disease especially 
asthma are more complicated in mechanism than allergic rhinitis and the patients usually 
have bronchial hyper reactivity. The main antihistaminic action which act on AR occur at 
the lower doses of N. sativa.(37) While anti-inflammatory action to treat asthma needs higher 
doses for longer period.(27,38) . b) High IgE level which reflects allergen exposure and 
correlate with worse atopic state. There are 2-4 fold variations in serum IgE levels with 
seasonal allergic rhinitis from spring or summer pollens(46) or ragweed pollen (47). Peak IgE 
levels are usually reached about 4-6 weeks after the peak pollination period and then 
decline to a nadir just prior to the subsequent pollination season .Higher IgE level always 
correlates with a bad clinical features and a more resistance to treatment. c) Gender, Poor 
response in females may be because of, hormonal changes, more allergen exposure to 
females (agricultural areas depend mainly on female work). These are leading to many 
exacerbations which in turn leading to a more chronic symptoms with a more severe 
condition and a more resistance to treatment. d) Perennial type which is the year round 
exposure to allergen leads to more nasal hyperreactivity with a more severe cases due to 
non specific hyperactivity that leads to chronic disease with a more stubborn to treatment. f) 
High percentage of atopic family history: This makes the patients more vulnerable to 
allergic disorders at earlier ages than non atopic families patients. Earlier disease, mainly 
leads to more severe attacks in the future, because more nasal hyper reactivity, high IgE 
level and multiple allergic disease may happen. g) Older ages: They have more nasal hyper 
reactivity which is due to more allergen exposures and more attacks, in addition to more 
chronic disease which leads to non specific stimulation of nasal mucosa which in turn leads 
to more stubborn to treatment. 
Treatment cessation lead to high rate of recurrence rate. However, the rate of recurrence was 
more in mild group as compared to moderate and severe group. This variation was a 
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reflection of the better response to treatment in mild as compared to other two groups. Thus 
the response to treatment with black seed oil was severity driven. 
The side effects of N. sativa extract used in allergic rhinitis was considered trivial as 
compared with conventional drugs used for allergic rhinitis like steroids or even 
antihistamines. One of these side effects of systemic N. sativa use was mild diarrhea which 
did not affect the administration of the herb. Excessive nasal dryness was much more in 
topical use; this may be due to more potent anti cholinergic effect in topical use than 
systemic use.  
6. Conclusions 
Systemic use of N. Sativa extract is effective in mild and moderate allergic rhinitis 
symptoms. Factors that may influence the response to systemic N.S treatment in allergic 
rhinitis include; multiple allergic diseases with high serum IgE level and atopic family 
diathesis, gender, perennial type, old age group patients. Side effects of N. Sativa extract use 
are trivial and easily controlled. Nigella sativa extract has proved to have a strong 
therapeutic effect in allergic rhinitis.  
7. Recommendations 
N.S extract oil has proved to be very effective in the treatment of AR so it is recommended 
as adjuvant therapy in patients treated with immunotherapy or conventional treatment. 
Conduction of long period treatment course clinical trial to elaborate the recurrence rate is 
warranted. To plan and conduct studies of longer periods and higher doses to clarify the 
therapeutic effect of this herb. 
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